Quetzal Therapeutics

We are dedicated to transforming the future of medicine by addressing unmet medical needs in oncology and rare diseases.

[Quetzal Therapeutics @Quetzal_Tx]

Quetzal Tx has dosed their first patient in the QUATRO-APL study, a major milestone made possible by our PIs, site teams, partners, and employees.
QTX-2101 is investigational; safety and efficacy have not been established.
Read the full press release here: https://t.co/2SbWH3lDaT

[Quetzal Therapeutics @Quetzal_Tx]

Today, on #WorldCancerDay, we stand with patients, caregivers, clinicians, and advocates working to reduce the impact of cancer around the world.
#OncologyResearch #RareCancer #PatientFocusedResearch

[Quetzal Therapeutics @Quetzal_Tx]

We’re excited to share that QTX-2101, our oral arsenic trioxide capsule, has been granted FDA Fast Track designation for the treatment of acute promyelocytic leukemia!

Read the full press release here:
https://t.co/zcswpiEVpj

[Quetzal Therapeutics @Quetzal_Tx]

Great overview from FoCR on the challenges of comparator selection in global cancer trials. Valuable insights for anyone navigating multi-regional studies and diverse regulatory landscapes.

Reposting for educational discussion. Views expressed are those of the author.

[Friends of Cancer Research @CancerResrch]

How can global #cancer trials be designed when the standard of care (SOC) differs in every region? Our White Paper explores a 7-step structured "funnel approach" to comparator selection that progressively filters the broad landscape of potential SOCs. https://t.co/tz4b53t8Mf

[Quetzal Therapeutics @Quetzal_Tx]

At Quetzal Therapeutics, we’re committed to rare diseases like APL. Early detection saves lives, and innovation is making treatment safer and more accessible. Follow us for updates, insights, and resources to raise awareness. #APL #RareDisease

[Quetzal Therapeutics @Quetzal_Tx]

We’ve launched a Phase III trial for QTX-2101, our novel oral arsenic trioxide therapy for APL! APL has gone from fatal to curable, but challenges remain. QTX-2101 aims to deliver a next-gen, patient-friendly option to transform outcomes. Learn more: https://t.co/nXWRSz6vFA
#APL

[Rare Diseases @CheckOrphan]

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL) - For More Visit https://t.co/BKjqGiAtg4 #Leukemia #Acute_Promyelocytic_Leukemia #APL #Quetzal

[Quetzal Therapeutics @Quetzal_Tx]

Quetzal Therapeutics is now on X! We’re on a mission to transform the future of medicine by tackling unmet needs in oncology and rare diseases. Follow us for updates on our progress as we work to make a difference.
https://t.co/Uy8zv01Vpj
#Biotech #Oncology #RareDiseases